(E)-N-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-4-(4-methylpiperazin-1-yl)but-2-enamide

ID: ALA4787426

PubChem CID: 162667285

Max Phase: Preclinical

Molecular Formula: C29H36ClN7O4S

Molecular Weight: 614.17

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  COc1cc(NC(=O)/C=C/CN2CCN(C)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1

Standard InChI:  InChI=1S/C29H36ClN7O4S/c1-20(2)42(39,40)26-9-6-5-8-24(26)33-28-22(30)19-31-29(35-28)34-23-12-11-21(18-25(23)41-4)32-27(38)10-7-13-37-16-14-36(3)15-17-37/h5-12,18-20H,13-17H2,1-4H3,(H,32,38)(H2,31,33,34,35)/b10-7+

Standard InChI Key:  JFJBQYDTDVUFOI-JXMROGBWSA-N

Molfile:  

 
     RDKit          2D

 42 45  0  0  0  0  0  0  0  0999 V2000
   17.6150  -28.5769    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.7978  -28.5769    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   17.2064  -29.2846    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.9137  -26.5339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.9125  -27.3535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.6206  -27.7624    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.3302  -27.3530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.3274  -26.5303    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.6188  -26.1251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0386  -27.7605    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.7457  -27.3508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.2045  -27.7615    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.4971  -27.3523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5023  -26.5353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7957  -26.1262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0867  -26.5343    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0887  -27.3557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7958  -27.7611    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4507  -27.7587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1573  -27.3497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1564  -26.5316    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4431  -26.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7394  -26.5356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0925  -28.9894    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4508  -28.5759    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.1585  -28.9844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.3826  -28.5848    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0971  -29.8066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.2059  -26.1255    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   23.8629  -26.1209    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.5718  -26.5275    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2783  -26.1168    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5742  -27.3447    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.9872  -26.5234    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.6938  -26.1127    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4026  -26.5193    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.4009  -27.3354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1057  -27.7419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8146  -27.3347    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8142  -26.5166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1049  -26.1056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5220  -27.7439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  7 10  1  0
 10 11  1  0
  5 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 11 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 11  1  0
 18  2  1  0
  2 24  1  0
 19 25  1  0
 25 26  1  0
 24 27  1  0
 24 28  1  0
  4 29  1  0
 21 30  1  0
 30 31  1  0
 31 32  1  0
 31 33  2  0
 32 34  2  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 36 41  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 40 41  1  0
 39 42  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4787426

    ---

Associated Targets(Human)

ROS1 Tclin Proto-oncogene tyrosine-protein kinase ROS (2436 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ALK Tclin ALK tyrosine kinase receptor (7132 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KARPAS-299 (888 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCC78 (247 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H1975 (4994 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 614.17Molecular Weight (Monoisotopic): 613.2238AlogP: 4.55#Rotatable Bonds: 11
Polar Surface Area: 128.79Molecular Species: NEUTRALHBA: 10HBD: 3
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.55CX Basic pKa: 7.98CX LogP: 4.22CX LogD: 3.54
Aromatic Rings: 3Heavy Atoms: 42QED Weighted: 0.26Np Likeness Score: -1.57

References

1. Zhu M,Li W,Zhao T,Chen Y,Li T,Wei S,Guo M,Zhai X.  (2020)  Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.,  28  (20.0): [PMID:33069075] [10.1016/j.bmc.2020.115719]

Source